What is the clearest distinction between phenotypic drug discovery and target-based drug discovery?

Question

BlackTom AI · Accepted Answer

Phenotypic discovery begins with a desirable cellular, tissue, or organism-level phenotype and may identify the molecular target later; target-based discovery begins with a prespecified molecular target that is believed to modify disease.

1. Relevant knowledge points and concepts
- Phenotypic drug discovery (PDD): screens compounds for their ability to produce a desired phenotype (e.g., cell survival, differentiation, corrected cellular pathology, behavioral change in model organisms) without requiring prior knowledge of the molecular target. Target deconvolution can follow successful hits.
- Target-based drug discovery (TDD): starts with a validated molecular target (enzyme, receptor, ion channel, etc.) implicated in disease; screens or designs compounds to modulate that target’s activity in biochemical or cell-based assays.
- Assay types: PDD uses phenotypic or functional assays (high-content imaging, viability, physiological readouts); TDD uses biochemical or binding assays that measure target engagement or modulation.

2. Step-by-step reasoning
- Compare starting points: PDD = phenotype-first; TDD = target-first.
- Consider downstream steps: PDD often requires target identification after hit discovery; TDD inherently tests compounds against the predefined target.
- Impact on hit discovery: PDD can reveal novel mechanisms and polypharmacology; TDD is more direct for structure-based design and mechanism-based optimization.

3. Calculations/intermediate steps
- No numerical calculations are required. The logical intermediate step is mapping “start point” (phenotype vs molecular target) to typical workflows and outcomes.

4. Why the correct answer is correct
- The correct option precisely captures the fundamental operational difference: PDD screens for desirable phenotypes and may reveal targets afterward; TDD begins with a disease-modifying target and screens for modulators of that target.

5. Why the other options are incorrect
- “Phenotypic discovery does not make use of AI or high-content screening”: false — PDD commonly uses high-content imaging and increasingly AI for phenotypic analysis.
- “Both approaches always require the same primary assay design”: false — their primary assays differ (phenotypic functional assays vs target-specific biochemical/cell-based assays).
- “Phenotypic discovery begins with a predefined molecular target, while target-based discovery begins with animal behaviour”: reversed and incorrect.

6. Conclusion
The correct answer is: "Phenotypic discovery starts from a desirable phenotype and may identify the target later, while target-based discovery starts from a prespecified disease-modifying target," which matches the provided answer.

What is the clearest distinction between phenotypic drug discovery and target-based drug discovery?单项选择题

类似问题

During Dr Loo’s lecture on AI approaches to drug discovery, which biotechnology company was specifically highlighted as an example of using phenotypic drug discovery?

Is the following statement true or false? In the products of methylation-hydrolysis, every -OH group corresponds to the position of a glycosidic bond in the starting polysaccharide.

Which of the follwoing structures represents amylopectin?

Which of the following is true about an aldopentose?I. It is a monosaccharide.II. It contains a CHO groupIII. It is a disaccharide.IV. It is an oligosaccharide.

For stock A, we have 𝛽 𝑖 = 0.70. Suppose the expected market risk premium next year is 9% and the risk-free rate is 3%. What is the expected return of this stock based on the CAPM? (Please answer in % and round to 2 decimal places. If the answer is 8.057%, then in the box, write 8.06)

更多留学生实用工具

智能学习助手

风格化写作助手

论文查重助手

文献引用助手

课堂转译助手

课堂笔记助手

Quiz搜索助手

学校历年真题

智能刷题助手

智能匹配练习

希望你的学习变得更简单